Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)

Recruiting now

Conditions studied: Uterine Fibroid

In brief

This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.

Key facts

Study ID

NCT06153667

Run by

Merit Medical Systems, Inc.

People needed

100

Starts

2024-08-22

Expected to finish

2026-12-01

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Adult women ≥ 18 years old at the time of enrollment.
• Subject has symptomatic uterine fibroid(s), suitable to embolization.
• Subject provides written informed consent.

You may not qualify if…

• Subject is pregnant.
• Subject has suspected pelvic inflammatory disease or any other pelvic infection.
• Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).

Where it is running

• The Wesley Hospital — Brisbane, Australia (enrolling)
• Alfred Health — Sydney, Australia (enrolling)
• Royal Gwent Hospital (Aneurin Bevan UHB) — Newport, United Kingdom (enrolling)
• Astra Vascular/Astra Vein Treatment Center — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.